by AdoloreJTC24 | Apr 23, 2025 | Press Releases
DELRAY BEACH, FL / ACCESS Newswire / April 23, 2025 / Adolore BioTherapeutics (“Adolore” or the “Company”) is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to...
by AdoloreJTC24 | Feb 4, 2025 | Press Releases
DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics (“Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS...
by AdoloreJTC24 | Oct 2, 2024 | Press Releases
DELRAY BEACH, FL / October 2, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C....
by AdoloreJTC24 | Sep 24, 2024 | Press Releases
DELRAY BEACH, FL / September 24, 2024 / Adolore BioTherapeutics, Inc., (“Adolore” or the “Company”), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy...
by AdoloreJTC24 | Sep 4, 2024 | Press Releases
Patent and novel, potent CA8* nonopioid analgesic licensed by Adolore BioTherapeutics from the University of MiamiCompany is advancing development of rdHSV-CA8* gene therapy delivered intracellularly for the treatment of chronic osteoarthritis (OA) knee pain toward an...
by AdoloreJTC24 | Jul 30, 2024 | Press Releases
This publication validates Adolore's approach for the intracellular delivery of a non-opioid analgesic minigene to targeted sensory neurons via local administrationData provide a robust preclinical proof-of-concept for this JDNI8-rdHSV-based carbonic anhydrase-8...
